{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:27:49Z","timestamp":1761920869529,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.msard.2021.102908","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T03:19:53Z","timestamp":1616123993000},"page":"102908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Alemtuzumab in Covid era"],"prefix":"10.1016","volume":"51","author":[{"given":"Aniello","family":"Iovino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nunzio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Aruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-9567","authenticated-orcid":false,"given":"Lucia","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5123-2459","authenticated-orcid":false,"given":"Emanuele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9672-4577","authenticated-orcid":false,"given":"Stefano","family":"Tozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiore","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.msard.2021.102908_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"6505","key":"10.1016\/j.msard.2021.102908_bib0002","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.msard.2021.102908_bib0003","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2021.102908_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102192","article-title":"COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series","volume":"42","author":"Hughes","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102908_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102306","article-title":"Beatrizdel Rioa: COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies","volume":"44","author":"Meca-Lallanaa","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2021.102908_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102908_bib0007","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","author":"Maria","year":"2021","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.msard.2021.102908_bib0008","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","article-title":"Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study","volume":"41","author":"Costa","year":"2020","journal-title":"Neurol Sci"},{"issue":"7","key":"10.1016\/j.msard.2021.102908_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.msard.2021.102908_bib0010","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.3390\/jcm9124066","article-title":"Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg","volume":"9","author":"Capasso","year":"2020","journal-title":"J Clin Med"},{"issue":"18","key":"10.1016\/j.msard.2021.102908_bib0011","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"10229","key":"10.1016\/j.msard.2021.102908_bib0012","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2021.102908_bib0013","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/1352458520926459","article-title":"Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression","volume":"26","author":"Carandini","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2021.102908_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102314","article-title":"Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab","volume":"44","author":"Guevara","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102908_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102447","article-title":"COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID","volume":"46","author":"Fiorella","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2021.102908_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102297","article-title":"Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab","volume":"44","author":"Mat\u00edas-Guiu","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2021.102908_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102402","article-title":"COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab","volume":"45","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"8","key":"10.1016\/j.msard.2021.102908_bib0018","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2021.102908_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-020-01437-2","article-title":"Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2021.102908_bib0020","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.3389\/fimmu.2019.01883","article-title":"Vaccination in Multiple Sclerosis: Friend or Foe?","volume":"10","author":"Tobias","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.msard.2021.102908_bib0021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-020-00756-y","article-title":"Claire Kaori Chen: Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination","volume":"34","author":"Zheng","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.102908_bib0022","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2021.102908_bib0023","first-page":"1","article-title":"COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience","author":"Paolo","year":"2020","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.msard.2021.102908_bib0024","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2021.102908_bib0025","doi-asserted-by":"crossref","unstructured":"Shintaro Hojyo, Mona Uchida, Kumiko Tanaka: How COVID-19 induces cytokine storm with high mortality 2021. doi: 10.1186\/s41232-020-00146-3.","DOI":"10.1186\/s41232-020-00146-3"},{"key":"10.1016\/j.msard.2021.102908_bib0026","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.msard.2018.12.024","article-title":"Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis","volume":"28","author":"Iovino","year":"2019","journal-title":"Mult Scler Relat Disor"},{"key":"10.1016\/j.msard.2021.102908_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord"},{"year":"2021","key":"10.1016\/j.msard.2021.102908_bib0028"},{"issue":"22","key":"10.1016\/j.msard.2021.102908_bib0029","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","volume":"94","author":"Brownlee","year":"2020","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:09Z","timestamp":1761900849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"alternative-id":["S2211034821001759"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102908","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab in Covid era","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102908"}}